A retrospective study involving advanced NSCLC patients receiving gefitinib/erlotinib (n = 183), osimertinib (n = 150), or afatinib (n = 55) found that osimertinib significantly prolonged PFS in patients with BoM and the exon 19 deletion, compared to other EGFR–TKIs.41 This evidence concerns the gene GRHL2 and non-small cell lung carcinoma.